FDA panel rejects blenrep combo in myeloma over safety, dosing concerns
The combinations, bortezomib and dexamethasone and pomalidomide and dexamethasone, were evaluated in adults with R/R multiple myeloma who have received at least one
Multiple Myeloma
News
SOHO 2025
News
Video Interviews
Society Updates
We are in full countdown mode to SOHO 2025
Register at soho.click/2025.
EHA 2025
News
Heme professionals report high burnout in EHA member survey
Long hours, lack of support, and poor management were identified as contributors to burnout among hematology professionals, according to a survey presented at
Lymphoma
Aggressive B-Cell Lymphomas
News
Early data support glofitamab combo in high-risk LBCL
The CD20xCD3 bispecific antibody glofitamab was shown to have durable responses when combined with Pola-R-CHP or R-CHOP, according to results from the phase
EHA 2025
News
Video Interviews
Dr. Masarova discusses SURPASS-ET study at EHA 2025
Lucia Masarova, MD, assistant professor in the Division of Cancer Medicine at the University of Texas MD Anderson Cancer Center in Houston, discusses
Multiple Myeloma
SOHO Insider Podcast
The journey of belantamab mafodotin in multiple myeloma
Host Saad Usmani, MD, chief of the myeloma service at Memorial Sloan Kettering Cancer Center in New York City, and Sagar Lonial, MD,
Multiple Myeloma
News
FDA grants accelerated approval to linvoseltamab in relapsed or refractory myeloma
The US Food and Drug Administration has granted accelerated approval to linvoseltamab (Lynozyfic) in adults patients with relapsed or refractory multiple myeloma who
EHA 2025
News
Video Interviews
Low-intensity protocol targets MRD in ALL
In this video interview, Anastasia Vasileva, MD, a researcher at the National Research Center for Hematology in Moscow, discusses findings from a study
2025 ASCO
News
Dr. Kuykendall discusses VERIFY trial, rusfertide’s impact on PV treatment
Andrew Kuykendall, MD, assistant member in Malignant Hematology at Moffitt Cancer Center in Tampa, Florida, discusses the phase 3 VERIFY trial primary results,
Leukemia
Lymphoma
Multiple Myeloma
FDA removes REMS requirement for 6 CAR-T therapies
The US Food and Drug Administration (FDA) has eliminated the Risk Evaluation and Mitigation Strategies (REMS) for all currently approved BCMA- and CD19-directed